Article citationsMore>>

Cannon, C.P., Battler, A., Brindis, R.G., Cox, J.L., Ellis, S.G., Every, N.R., et al. (2001) American College of Cardiology Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients with Acute Coronary Syndromes. A Report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). Journal of the American College of Cardiology, 38, 2114-2130.
http://dx.doi.org/10.1016/S0735-1097(01)01702-8

has been cited by the following article:

• TITLE: Worsening Clinical Outcome with Increasing Number of So-Called Off-Label or Unapproved Indications for Use of Drug Eluting Stents

  AUTHORS: Anders M. Galløe, Ulrik Abildgaard, Henning Kelbæk, Niels Bligaard, Jørgen L. Jeppesen, Leif Thuesen, Peter R. Hansen

  KEYWORDS: Drug Eluting Stents

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.6 No.7, July 12, 2016

  ABSTRACT: Objective: We explored the impact of increasing number of off-label patient and lesion character-istics on 5-year clinical outcome following implantation of first generation drug eluting stents. Furthermore we tried to assess if stent performance might be improved if the off-label character-istics present were taken into account to guide the stent brand selection. Design: A total of 2888 coronary lesions treated with first generation drug eluting stents were classified for eventual presence of 18 different off-label characteristics and correlated to the 5-year clinical outcome by multiple stepwise Cox regression analysis. Results: The composite of cardiac death, myocardial infarction and target vessel revascularization (major adverse cardiac event, MACE) was 16.7% in cases with zero off-label characteristics and showed a stepwise increased rate up to 32.7% in cases with 5 off-label characteristics. The MACE rate for the sirolimus eluting stent appears to be 10% lower than the paclitaxel stent group and it may be further reduced by 10% - 18% if the off-label characteristics present in each case were taken into account to guide the stent brand selection. Conclusion: With increasing number of concomitantly appearing off-label characteristics there is a stepwise increase in MACE rate. The MACE rate may be reduced if the off-label characteristics were used to guide the stent brand selection.